Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.49 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.49 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.39 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.39 |
| ▸ | POLA1 | P09884 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26991473 | 0.91 | KDM4E (0.62) | KDM4ETAS1R3TAS1R1P2RY1POLB | |
| SCHEMBL24513568 | 0.90 | KDM4E (0.57) | KDM4ETAS1R3TAS1R1P2RY1POLB | |
| SCHEMBL29637907 | 0.90 | KDM4E (0.57) | KDM4ETAS1R3TAS1R1P2RY1POLB | |
| SCHEMBL29637899 | 0.90 | KDM4E (0.57) | KDM4ETAS1R3TAS1R1P2RY1POLB | |
| SCHEMBL24548428 | 0.90 | KDM4E (0.57) | KDM4ETAS1R3TAS1R1P2RY1POLB | |
| SCHEMBL24513567 | 0.90 | KDM4E (0.57) | KDM4ETAS1R3TAS1R1P2RY1POLB | |
| SCHEMBL24548434 | 0.90 | KDM4E (0.57) | KDM4ETAS1R3TAS1R1P2RY1POLB | |
| SCHEMBL25382010 | 0.90 | KDM4E (0.63) | KDM4ETAS1R3TAS1R1P2RY1POLB | |
| SCHEMBL9703289 | 0.88 | KDM4E (0.74) | KDM4ETAS1R3TAS1R1P2RY1POLB | |
| SCHEMBL22315215 | 0.88 | KDM4E (0.74) | KDM4ETAS1R3TAS1R1P2RY1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3854799-A1 | CYCLIC DINUCLEOTIDE ANALOGUE, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION | Shanghai de Novo Pharmatech Co., Ltd. (CN) | 2021-07-28 | — | — | EP | disclosed |